A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
AVITA Medical, Inc.
RCEL
$129M
Mkt Cap
$4.61
+0.00%
AVITA Medical, Inc. (RCEL) has a 5-year average return on invested capital (ROIC) of -46.4%. This is below average and may indicate limited pricing power.
AVITA Medical, Inc. (RCEL) has a market capitalization of $129M. It is classified as a small-cap stock.
AVITA Medical, Inc. (RCEL) does not currently pay a regular dividend.
AVITA Medical, Inc. (RCEL) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
AVITA Medical, Inc. (RCEL) reported annual revenue of $72 million in its most recent fiscal year, based on SEC EDGAR filings.
AVITA Medical, Inc. (RCEL) has a net profit margin of -67.8%. The company is currently unprofitable.
AVITA Medical, Inc. (RCEL) generated $-32 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
AVITA Medical is a leading therapeutic acute wound care company delivering transformative solutions designed to optimize wound healing, accelerate patient recovery, and improve clinical and economic outcomes across the continuum of acute wound management. Our technologies address critical healing needs arising from burns, traumatic injuries and surgical repairs, through a portfolio of proprietary and complementary products that support wound bed preparation, definitive closure, and recovery. Our current commercial portfolio includes RECELL® (“RECELL”), and two complementary wound care products, PermeaDerm® and Cohealyx™, which together support a comprehensive standard of care for acute wounds. At the forefront of our portfolio is RECELL, approved by the United States Food & Drug Administration (the “FDA”) for the treatment of thermal burn wounds and full-thickness skin defects.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 72M | 72M | 64M | 50M | 34M | 29M |
| Net Income | -49M | -49M | -62M | -35M | -27M | -27M |
| EPS | $-1.74 | $-1.74 | $-2.39 | $-1.40 | $-1.06 | $1.17 |
| Free Cash Flow | -32M | -32M | -58M | -39M | -20M | -27M |
| ROIC | -175.4% | -299.7% | -91.2% | -40.8% | -28.2% | -25.4% |
| Gross Margin | 9.8% | 9.8% | 85.8% | 31.1% | 32.4% | 79.6% |
| Debt/Equity | 0.00 | -2.77 | 10.22 | 0.86 | 0.01 | 0.11 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -43M | -43M | -57M | -43M | -28M | -27M |
| Operating Margin | -59.4% | -59.4% | -88.1% | -85.1% | -79.9% | -90.8% |
| ROE | 0.0% | - | -231.0% | -52.9% | -28.2% | -25.4% |
| Shares Outstanding | 28M | 28M | 26M | 25M | 25M | 25M |
| Metric | 2017 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | N/A | N/A | N/A | N/A | 29M | 34M | 50M | 64M | 72M | 72M |
| Gross Margin | N/A | N/A | N/A | N/A | 79.6% | 32.4% | 31.1% | 85.8% | 9.8% | 9.8% |
| R&D | 11M | 6.3M | 8.0M | 9.2M | 15M | 14M | 21M | 20M | 21M | 21M |
| SG&A | N/A | 9.4M | 15M | 33M | 22M | 23M | 28M | 33M | 27M | 27M |
| EBIT | -14M | -14M | -26M | -43M | -27M | -28M | -43M | -57M | -43M | -43M |
| Op. Margin | N/A | N/A | N/A | N/A | -90.8% | -79.9% | -85.1% | -88.1% | -59.4% | -59.4% |
| Net Income | -13M | -13M | -25M | -42M | -27M | -27M | -35M | -62M | -49M | -49M |
| Net Margin | N/A | N/A | N/A | N/A | -90.9% | -77.5% | -70.6% | -96.3% | -67.8% | -67.8% |
| Non-Recurring | 0 | 0 | -2K | -259K | 0 | -3K | -83K | -107K | -595K | -595K |
| Returns on Capital | ||||||||||
| ROIC | N/M | -77.9% | -144.0% | -90.2% | -25.4% | -28.2% | -40.8% | -91.2% | N/M | -175.4% |
| ROE | -209.8% | -141.8% | -144.0% | -90.2% | -25.4% | -28.2% | -52.9% | -231.0% | N/A | 0.0% |
| ROA | -172.5% | -84.1% | -102.9% | -77.7% | -22.9% | -24.9% | -33.7% | -64.6% | -71.4% | -86.2% |
| Cash Flow | ||||||||||
| Op. Cash Flow | -8.6M | -13M | -19M | -23M | -26M | -19M | -38M | -49M | -31M | -31M |
| Free Cash Flow | -9.0M | -13M | -20M | -23M | -27M | -20M | -39M | -58M | -32M | -32M |
| Owner Earnings | -8.6M | -14M | -21M | -40M | -32M | -27M | -47M | -64M | -43M | -43M |
| CapEx | 433K | 365K | 1.0M | 590K | 894K | 452K | 1.4M | 9.2M | 1.0M | 1.0M |
| Maint. CapEx | 0 | 110K | 269K | 465K | 715K | 568K | 632K | 1.1M | 2.3M | 2.3M |
| Growth CapEx | N/A | 255K | 752K | 125K | 179K | 0 | 749K | 8.0M | 0 | 0 |
| D&A | 0 | 110K | 269K | 465K | 715K | 568K | 632K | 1.1M | 2.3M | 2.3M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | N/A | 1.4M | 1.9M | 16M | 5.7M | 7.0M | 8.4M | 13M | 9.5M | 9.5M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | -78M | -47M | 10M | 28M | 36M |
| Cash & Equiv. | 3.8M | 11M | 20M | 74M | 56M | 18M | 22M | 14M | 10M | 10M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | 40M | 42M | 0 | N/A |
| Debt/Equity | 0.50 | 0.29 | 0.24 | 0.14 | 0.11 | 0.01 | 0.86 | 10.22 | -2.77 | 0.00 |
| Interest Coverage | -1065.9 | -659.1 | -945.5 | -1293.3 | -1206.4 | -1719.1 | -37.3 | -10.6 | -8.5 | -8.5 |
| Equity | 5.1M | 14M | 21M | 72M | 105M | 85M | 49M | 4.5M | -17M | -17M |
| Total Assets | 7.3M | 23M | 26M | 82M | 116M | 98M | 112M | 80M | 56M | 56M |
| Total Liabilities | 2.5M | 4.0M | 5.0M | 10M | 11M | 13M | 62M | 75M | 73M | 73M |
| Intangibles | N/A | N/A | 225K | 364K | 886K | 465K | 487K | 5.6M | 5.6M | 5.6M |
| Retained Earnings | -132M | -149M | -153M | -195M | -236M | -263M | -298M | -360M | -408M | -408M |
| Working Capital | N/A | 18M | 20M | 71M | 83M | 77M | 91M | 37M | -27M | -27M |
| Current Assets | 387K | 22M | 24M | 78M | 92M | 87M | 104M | 57M | 35M | 35M |
| Current Liabilities | N/A | 3.9M | 4.5M | 7.7M | 9.1M | 11M | 13M | 20M | 63M | 63M |
| Per Share Data | ||||||||||
| EPS | -8.60 | 119.19 | 135.72 | 180.09 | 1.17 | -1.06 | -1.40 | -2.39 | -1.74 | -1.74 |
| Owner EPS | -0.02 | N/A | N/A | N/A | -1.28 | -1.06 | -1.86 | -2.46 | -1.54 | -1.54 |
| Book Value | 0.01 | N/A | N/A | N/A | 4.14 | 3.36 | 1.94 | 0.17 | -0.60 | -0.60 |
| Cash Flow/Share | -0.02 | N/A | N/A | N/A | -1.02 | -0.76 | -1.50 | -1.89 | -1.12 | -1.66 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 379.4M | N/A | N/A | N/A | 25.3M | 25.2M | 25.3M | 25.9M | 27.9M | 27.9M |
| Valuation | ||||||||||
| P/E Ratio | N/A | 4.0 | 28.6 | 9.1 | 10.1 | 6.0 | N/A | N/A | N/A | -2.6 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 366.6 | N/A | N/A | 6.5 | 2.9 | 2.0 | 7.4 | 77.6 | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | 16.7 | 5.2 | 6.7 | 4.7 | 2.5 | 1.8 |
| FCF Yield | -0.5% | N/A | N/A | -5.0% | -8.9% | -11.8% | -10.9% | -16.6% | -33.5% | -25.0% |
| Market Cap | 1.9B | N/A | N/A | 468M | 300M | 165M | 361M | 349M | 96M | 129M |
| Avg. Price | 6.65 | 5.68 | 27.87 | 29.87 | 19.30 | 6.96 | 13.35 | 11.67 | 6.49 | 4.61 |
| Year-End Price | 4.95 | 5.45 | 44.65 | 18.80 | 11.86 | 6.43 | 14.27 | 13.49 | 3.44 | 4.61 |
AVITA Medical, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 47.8%. At current prices, the estimated annualized return to fair value is -8.4%.
AVITA Medical, Inc. (RCEL) reported earnings per share (EPS) of $-1.74 in its most recent fiscal year.
AVITA Medical, Inc. (RCEL) has a 5-year average gross margin of 47.8%. This indicates decent pricing power.
The Ledger Terminal provides 9 years of financial data for AVITA Medical, Inc. (RCEL), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
AVITA Medical, Inc. (RCEL) has a book value per share of $-0.60, based on its most recent annual SEC filing.